Investment Adventures in Emerging Markets

China’s Sci-Tech Board: Hope or Hype?
Asia

China’s Sci-Tech Board: Hope or Hype?

China will be launching a Nasdaq-style stock market for technology and research-driven companies to list and raise capital. While it has some detractors, Franklin Templeton Emerging Markets Equity believes this upcoming board is of strategic importance to China. Jason Zhu, director of portfolio management—China Equities, says it could rev up China’s emergence as a research powerhouse and help emerging companies grow into industry champions, but the team will be watching at least two key factors—the quality of companies listed and their valuations.

Are EM Small-Cap Stocks Due for a Rebound?
Perspective

Are EM Small-Cap Stocks Due for a Rebound?

“The EM small-cap space remains attractive to us, partly because many of the headwinds in 2018 have already been priced into valuations or are likely to abate this year.” - Franklin Templeton Emerging Markets Equity team

A Prescription for Innovation
Perspective

A Prescription for Innovation

The word “innovation” is typically associated with technology, but innovation comes in many forms and across many industries. Franklin Templeton Emerging Markets Equity’s Krzysztof Musialik sees innovation taking place within the health care and pharmaceuticals industries in emerging markets—even driving change in developed markets.

Getting to Know Chetan Sehgal
Perspective

Getting to Know Chetan Sehgal

“In the 23 years I’ve been investing in emerging markets, the biggest change I’ve seen has been improvements in corporate governance. Sometimes, investors don’t realize how much difference legal, regulatory and institutional frameworks make, especially in emerging-market economies.” Chetan Sehgal, senior managing director, director of portfolio management, Franklin Templeton Emerging Markets Equity